Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
The study aim is to assess the immunological and clinical response in basal cell carcinoma
(BCC) treated with ablative fractionated laser (AFL) as monotherapy and compare with BCC
treated with combination-therapy of AFL and the anti-PD1-drug nivolumab and with nivolumab as
monotherapy.